SEC Filings
Fate Therapeutics Expects Funding Through Mid-2028 As Lupus Kidney-Disease Trial Advances
A $15 million research grant supports the kidney-disease study, while spending cuts helped narrow the quarterly loss.
FATE
Fate Therapeutics (FATE) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Fate Therapeutics Opens $100 Million Share-Sale Option, Replacing Jefferies With Leerink
The optional program lets Fate set sale limits and pays Leerink up to 3% of gross proceeds.
SEC Filings
California's Stem Cell Agency Awards Fate Therapeutics $15 Million To Run A Mid-Stage Lupus Kidney Trial
The CIRM grant funds RECLAIM-LN, a potentially registrational trial of FT819 off-the-shelf CAR T-cell therapy in roughly 53 patients.